ROFLUMILAST for psoriasis improved Global Assessment scores and was well tolerated versus placebo by Week 8 in a systematic review.
Why Roflumilast for Psoriasis Was Studied
Psoriasis is a chronic inflammatory skin disease that can significantly affect quality of life, with erythema, thickening, and scaling as common clinical hallmarks. The most common phenotype is plaque psoriasis, accounting for the majority of cases and ranging from localized disease to extensive involvement. Topical corticosteroids remain widely used, but longer-term use can raise safety and tolerability concerns, reinforcing interest in alternative options. Roflumilast, a potent phosphodiesterase 4 inhibitor, has been explored as a treatment approach for psoriasis in controlled trials.